Upgrade to SI Premium - Free Trial

Denali Therapeutics (DNLI)

23.69 -0.14 (0.59%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Denali Therapeutics Inc. (DNLI) PT Raised to $35 at Deutsche Bank July 17, 2026 7:17 AM - StreetInsider Denali Therapeutics (DNLI) call put ratio 1.3 calls to 1 put as share price up 2.2% July 13, 2026 2:20 PM - StreetInsider JPMorgan Resumes Denali Therapeutics Inc. (DNLI) at Overweight July 13, 2026 3:14 AM - StreetInsider Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Ba July 9, 2026 4:01 PM - StreetInsider Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc. July 8, 2026 11:30 AM - SEC Filing June 22, 2026 9:26 AM - StreetInsider Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) June 22, 2026 9:26 AM - StreetInsider Form 8-K Denali Therapeutics Inc. For: Jun 12 June 18, 2026 8:02 AM - SEC Filing Denali Therapeutics to sell priority review voucher for $195M June 18, 2026 8:00 AM - StreetInsider Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million June 18, 2026 8:00 AM - StreetInsider UBS Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) June 16, 2026 9:27 AM - StreetInsider Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: FLATLEY JAY T June 5, 2026 4:46 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Klein Peter S June 5, 2026 4:46 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Krognes Steve E. June 5, 2026 4:46 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Schenkein David P June 5, 2026 4:45 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Thornberry Nancy June 5, 2026 4:45 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Van Hauwermeiren Timothy June 5, 2026 4:45 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: Cook Jennifer E. June 5, 2026 4:43 PM - SEC Filing Form 4 Denali Therapeutics Inc. For: Jun 03 Filed by: 667, L.P. June 5, 2026 4:28 PM - SEC Filing Form 8-K Denali Therapeutics Inc. For: Jun 03 June 4, 2026 6:02 AM - SEC Filing Denali Therapeutics Inc. (DNLI) PT Lowered to $28 at Evercore ISI May 27, 2026 1:47 PM - StreetInsider Denali Therapeutics Inc. (DNLI) PT Lowered to $35 at Morgan Stanley May 26, 2026 7:44 AM - StreetInsider Form 8-K Denali Therapeutics Inc. For: May 21 May 22, 2026 6:01 AM - SEC Filing Biogen and Denali discontinue Parkinson's drug after trial fails May 21, 2026 6:00 PM - StreetInsider Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease May 21, 2026 6:00 PM - StreetInsider Form SCHEDULE 13G Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc. May 15, 2026 10:07 AM - SEC Filing Denali Therapeutics Inc. (DNLI) PT Lowered to $40 at Morgan Stanley May 14, 2026 8:52 AM - StreetInsider Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 3c May 7, 2026 5:57 PM - StreetInsider Form 10-Q Denali Therapeutics Inc. For: Mar 31 May 7, 2026 4:14 PM - SEC Filing Form 8-K Denali Therapeutics Inc. For: May 07 May 7, 2026 4:04 PM - SEC Filing Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 4:01 PM - StreetInsider Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: FMR LLC May 6, 2026 11:14 AM - SEC Filing Full Article List